O
Omid C. Farokhzad
Researcher at Brigham and Women's Hospital
Publications - 340
Citations - 75194
Omid C. Farokhzad is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Drug delivery & Aptamer. The author has an hindex of 110, co-authored 329 publications receiving 64226 citations. Previous affiliations of Omid C. Farokhzad include Beth Israel Deaconess Medical Center & Columbia University.
Papers
More filters
Journal ArticleDOI
Hybrid lipid–polymer nanoparticles for sustained siRNA delivery and gene silencing
Jinjun Shi,Yingjie Xu,Xiaoyang Xu,Xi Zhu,Xi Zhu,Eric Pridgen,Jun Wu,Alexander R. Votruba,Archana Swami,Bruce R. Zetter,Omid C. Farokhzad,Omid C. Farokhzad +11 more
TL;DR: An NP platform with sustained siRNA-release properties, which can be self-assembled using biodegradable and biocompatible polymers and lipids, and which generates more effective tumor cell growth inhibition in vitro and in vivo than the lipofectamine complexes is presented.
Patent
Nanostructures for drug delivery
TL;DR: In this paper, the authors present compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer using a platinum(IV) therapeutically active precursor.
Journal ArticleDOI
Oral Insulin Delivery Platforms: Strategies To Address the Biological Barriers.
TL;DR: An overview of biological barriers to oral insulin delivery is provided, significant technological advances are summarized, and future perspectives in oral insulin formulations as well as their hypoglycaemic effects are outlined.
Patent
Aptamer-directed drug delivery
Omid C. Farokhzad,Sangyong Jon,Vaishali Bagalkot,Liangfang Zhang,Benjamin A. Teply,Etgar Levy-Nissenbaum,Robert Langer +6 more
TL;DR: In this paper, the authors provide systems, methods, and compositions for targeted delivery of a therapeutic agent organs, tissues, cells, extracellular matrix components, and intracellular compartments.
Journal ArticleDOI
Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr-/- Mice.
Mi Kyung Yu,Jaume Amengual,Arjun Menon,Nazila Kamaly,Nazila Kamaly,Felix Zhou,Xiao-Ding Xu,Phei Er Saw,Seung-Joo Lee,Kevin Si,Carleena Angelica Ortega,Won Il Choi,In Hyun Lee,Yazan Bdour,Jinjun Shi,Morteza Mahmoudi,Sangyong Jon,Edward A. Fisher,Omid C. Farokhzad,Omid C. Farokhzad +19 more
TL;DR: Findings suggest a new form of LXR‐based therapeutics capable of enhanced delivery of the LXR agonist to atherosclerotic lesions without altering hepatic lipid metabolism.